keyword
MENU ▼
Read by QxMD icon Read
search

Sabatine

keyword
https://www.readbyqxmd.com/read/27751237/2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy-in-patients-with-coronary-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines
#1
Glenn N Levine, Eric R Bates, John A Bittl, Ralph G Brindis, Stephan D Fihn, Lee A Fleisher, Christopher B Granger, Richard A Lange, Michael J Mack, Laura Mauri, Roxana Mehran, Debabrata Mukherjee, L Kristin Newby, Patrick T O'Gara, Marc S Sabatine, Peter K Smith, Sidney C Smith, Jonathan L Halperin, Glenn N Levine, Sana M Al-Khatib, Kim K Birtcher, Biykem Bozkurt, Ralph G Brindis, Joaquin E Cigarroa, Lesley H Curtis, Lee A Fleisher, Federico Gentile, Samuel Gidding, Mark A Hlatky, John S Ikonomidis, José A Joglar, Susan J Pressler, Duminda N Wijeysundera
No abstract text is available yet for this article.
November 2016: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/27673306/association-between-lowering-ldl-c-and-cardiovascular-risk-reduction-among-different-therapeutic-interventions-a-systematic-review-and-meta-analysis
#2
Michael G Silverman, Brian A Ference, Kyungah Im, Stephen D Wiviott, Robert P Giugliano, Scott M Grundy, Eugene Braunwald, Marc S Sabatine
IMPORTANCE: The comparative clinical benefit of nonstatin therapies that reduce low-density lipoprotein cholesterol (LDL-C) remains uncertain. OBJECTIVE: To evaluate the association between lowering LDL-C and relative cardiovascular risk reduction across different statin and nonstatin therapies. DATA SOURCES AND STUDY SELECTION: The MEDLINE and EMBASE databases were searched (1966-July 2016). The key inclusion criteria were that the study was a randomized clinical trial and the reported clinical outcomes included myocardial infarction (MI)...
September 27, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27576775/prevention-of-stroke-with-ticagrelor-in-patients-with-prior-myocardial-infarction-insights-from-pegasus-timi-54-prevention-of-cardiovascular-events-in-patients-with-prior-heart-attack-using-ticagrelor-compared-to-placebo-on-a-background-of-aspirin-thrombolysis
#3
Marc P Bonaca, Shinya Goto, Deepak L Bhatt, P Gabriel Steg, Robert F Storey, Marc Cohen, Erica Goodrich, Laura Mauri, Ton Oude Ophuis, Mikhail Ruda, Jindřich Špinar, Ki-Bae Seung, Dayi Hu, Anthony J Dalby, Eva Jensen, Peter Held, David A Morrow, Eugene Braunwald, Marc S Sabatine
BACKGROUND: In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population...
September 20, 2016: Circulation
https://www.readbyqxmd.com/read/27548077/antiplatelet-therapy-for-long-term-secondary-prevention-after-myocardial-infarction
#4
Marc P Bonaca, Marc S Sabatine
No abstract text is available yet for this article.
September 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27532444/editorial-on-pegasus-timi-54
#5
EDITORIAL
Giulia Magnani, Marc P Bonaca, Marc S Sabatine
No abstract text is available yet for this article.
October 2015: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/27444932/aptamer-based-proteomic-profiling-reveals-novel-candidate-biomarkers-and-pathways-in-cardiovascular-disease
#6
Debby Ngo, Sumita Sinha, Dongxiao Shen, Eric W Kuhn, Michelle J Keyes, Xu Shi, Mark D Benson, John F O'Sullivan, Hasmik Keshishian, Laurie A Farrell, Michael A Fifer, Ramachandran S Vasan, Marc S Sabatine, Martin G Larson, Steven A Carr, Thomas J Wang, Robert E Gerszten
BACKGROUND: Single-stranded DNA aptamers are oligonucleotides of ≈50 base pairs in length selected for their ability to bind proteins with high specificity and affinity. Emerging DNA aptamer-based technologies may address limitations of existing proteomic techniques, including low sample throughput, which have hindered proteomic analyses of large cohorts. METHODS: To identify early biomarkers of myocardial injury, we applied an aptamer-based proteomic platform that measures 1129 proteins to a clinically relevant perturbational model of planned myocardial infarction (PMI), patients undergoing septal ablation for hypertrophic cardiomyopathy...
July 26, 2016: Circulation
https://www.readbyqxmd.com/read/27440003/atherothrombotic-risk-stratification-and-the-efficacy-and-safety-of-vorapaxar-in-patients-with-stable-ischemic-heart-disease-and-previous-myocardial-infarction
#7
Erin A Bohula, Marc P Bonaca, Eugene Braunwald, Philip E Aylward, Ramon Corbalan, Gaetano M De Ferrari, Ping He, Basil S Lewis, Piera A Merlini, Sabina A Murphy, Marc S Sabatine, Benjamin M Scirica, David A Morrow
BACKGROUND: Patients with stable ischemic heart disease and previous myocardial infarction (MI) vary in their risk for recurrent cardiovascular events. Atherothrombotic risk assessment may be useful to identify high-risk patients who have the greatest potential to benefit from more intensive secondary preventive therapy such as treatment with vorapaxar. METHODS: We identified independent clinical indicators of atherothrombotic risk among 8598 stable, placebo-treated patients with a previous MI followed up for 2...
July 26, 2016: Circulation
https://www.readbyqxmd.com/read/27438319/long-term-tolerability-of-ticagrelor-for-the-secondary-prevention-of-major-adverse-cardiovascular-events-a-secondary-analysis-of-the-pegasus-timi-54-trial
#8
Marc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, P Gabriel Steg, Robert Storey, Marc Cohen, Julia Kuder, Kyungah Im, Giulia Magnani, Andrzej Budaj, Pierre Theroux, Christian Hamm, Jindrich Špinar, Robert G Kiss, Anthony J Dalby, Felix A Medina, Frederic Kontny, Philip E Aylward, Eva C Jensen, Peter Held, Eugene Braunwald, Marc S Sabatine
IMPORTANCE: In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo. OBJECTIVE: To investigate the reasons and timing of discontinuation of treatment with ticagrelor among stable patients prior myocardial infarction. DESIGN, SETTING, AND PARTICIPANTS: In the PEGASUS-TIMI 54 trial, 21 162 stable outpatients with prior myocardial infarction were randomly assigned to 90 mg of ticagrelor twice daily, 60 mg of ticagrelor twice daily, or placebo, with all of the patients receiving a low dose of aspirin...
July 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27438098/the-prospects-for-cardiovascular-proteomics-a-glass-approaching-half-full
#9
Mark D Benson, Marc S Sabatine, Robert E Gerszten
No abstract text is available yet for this article.
June 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27437651/nurturing-nature-exploring-the-possible-role-of-epigenetics-in-dyslipidemia
#10
Marc S Sabatine
No abstract text is available yet for this article.
April 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27422124/focus-on-pcsk9-inhibitors-from-genetics-to-clinical-practice
#11
Marc S Sabatine, James A Underberg, Michael Koren, Seth J Baum
Elevation of low-density lipoprotein cholesterol (LDL-C) is an important cause of atherosclerotic cardiovascular disease (ASCVD). Over the years, clinical outcome studies with LDL-C lowering agents have revealed that reducing LCL-C levels is effective in reducing rates of major ASCVD events. Although secondary factors play a role in clinical expression, severe lipid disorders often have a strong genetic component. Genetic revelations have provided novel targets for improving LDL-C management in high-risk individuals...
October 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27327798/using-aptamer-based-technology-to-probe-the-plasma-proteome-for-cardiovascular-disease-prediction
#12
EDITORIAL
Marc S Sabatine
No abstract text is available yet for this article.
June 21, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27207959/multimarker-risk-stratification-in-patients-with-acute-myocardial-infarction
#13
Michelle L O'Donoghue, David A Morrow, Christopher P Cannon, Petr Jarolim, Nihar R Desai, Matthew W Sherwood, Sabina A Murphy, Robert E Gerszten, Marc S Sabatine
BACKGROUND: Several biomarkers have individually been shown to be useful for risk stratification in patients with acute myocardial infarction (MI). The optimal multimarker strategy remains undefined. METHODS AND RESULTS: Biomarkers representing different pathobiological axes were studied, including myocardial stress/structural changes (NT-pro B-type natriuretic peptide [NT-proBNP], midregional proatrial natriuretic peptide [MR-proANP], suppression of tumorigenicity 2 [ST2], galectin-3, midregional proadrenomedullin [MR-proADM], and copeptin), myonecrosis (troponin T), and inflammation (myeloperoxidase [MPO], high sensitivity C-reactive protein [hsCRP], pregnancy-associated plasma protein A [PAPP-A], and growth-differentiation factor-15 [GDF-15]), in up to 1258 patients from Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28), a randomized trial of clopidogrel in ST-elevation MI (STEMI)...
May 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27179740/the-china-acute-myocardial-infarction-cami-registry-a-national-long-term-registry-research-education-integrated-platform-for-exploring-acute-myocardial-infarction-in-china
#14
Haiyan Xu, Wei Li, Jingang Yang, Stephen D Wiviott, Marc S Sabatine, Eric D Peterson, Ying Xian, Matthew T Roe, Wei Zhao, Yang Wang, Xinran Tang, Xuan Jia, Yuan Wu, Runlin Gao, Yuejin Yang
BACKGROUND: Acute myocardial infarction (AMI) has become a major cause of hospitalization and mortality in China. There has been limited data to date available to characterize AMI presentation, contemporary patterns of medical care, and outcomes in China. AIMS: The CAMI Registry is a national project with the objectives to timely obtain real-world knowledge about AMI patients and to provide the platform for clinical research, guide preventive measures and care quality improvement efforts in China...
May 2016: American Heart Journal
https://www.readbyqxmd.com/read/27102113/pcsk9-inhibition-mediated-reduction-in-lp-a-with-evolocumab-an-analysis-of-10-clinical-trials-and-the-ldl-receptor-s-role
#15
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, Michael J Koren, Dirk Blom, Nabil G Seidah, Narimon Honarpour, Armando Lira, Allen Xue, Padmaja Chiruvolu, Simon Jackson, Mei Di, Matthew Peach, Ransi Somaratne, Scott M Wasserman, Rob Scott, Evan A Stein
Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases Lp(a). The potential mechanisms were assessed. A pooled analysis of Lp(a) and LDL cholesterol (LDL-C) in 3,278 patients from 10 clinical trials (eight phase 2/3; two extensions) was conducted. Within each parent study, biweekly and monthly doses of evolocumab statistically significantly reduced Lp(a) at week 12 versus control (P < 0...
June 2016: Journal of Lipid Research
https://www.readbyqxmd.com/read/27046162/ticagrelor-for-prevention-of-ischemic-events-after-myocardial-infarction-in-patients-with-peripheral-artery-disease
#16
Marc P Bonaca, Deepak L Bhatt, Robert F Storey, Ph Gabriel Steg, Marc Cohen, Julia Kuder, Erica Goodrich, José C Nicolau, Alexander Parkhomenko, José López-Sendón, Mikael Dellborg, Anthony Dalby, Jindřich Špinar, Philip Aylward, Ramón Corbalán, Maria Teresa B Abola, Eva C Jensen, Peter Held, Eugene Braunwald, Marc S Sabatine
BACKGROUND: Peripheral artery disease (PAD) is associated with heightened ischemic and bleeding risk in patients with prior myocardial infarction (MI). OBJECTIVES: This study evaluated the efficacy and safety of ticagrelor on major cardiovascular (CV) events and major adverse limb events in patients with PAD and a prior MI. METHODS: PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin...
June 14, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27046160/reduction-in-ischemic-events-with-ticagrelor-in-diabetic-patients-with-prior-myocardial-infarction-in-pegasus-timi-54
#17
Deepak L Bhatt, Marc P Bonaca, Sameer Bansilal, Dominick J Angiolillo, Marc Cohen, Robert F Storey, Kyungah Im, Sabina A Murphy, Peter Held, Eugene Braunwald, Marc S Sabatine, Ph Gabriel Steg
BACKGROUND: Patients with diabetes appear to be at elevated risk of atherothrombotic events. OBJECTIVES: The purpose of this study was to determine the effect of antiplatelet therapy with ticagrelor on recurrent ischemic events in patients with diabetes and prior myocardial infarction (MI). METHODS: We examined the subgroups of patients with diabetes (n = 6,806) and without diabetes (n = 14,355) from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54), in which 21,162 patients with a history of MI 1 to 3 years prior and with additional risk factors were randomized to ticagrelor (90 or 60 mg twice daily) or placebo...
June 14, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27043082/effect-of-losmapimod-on-cardiovascular-outcomes-in-patients-hospitalized-with-acute-myocardial-infarction-a-randomized-clinical-trial
#18
RANDOMIZED CONTROLLED TRIAL
Michelle L O'Donoghue, Ruchira Glaser, Matthew A Cavender, Philip E Aylward, Marc P Bonaca, Andrzej Budaj, Richard Y Davies, Mikael Dellborg, Keith A A Fox, Jorge Antonio T Gutierrez, Christian Hamm, Robert G Kiss, František Kovar, Julia F Kuder, Kyung Ah Im, John J Lepore, Jose L Lopez-Sendon, Ton Oude Ophuis, Alexandr Parkhomenko, Jennifer B Shannon, Jindrich Spinar, Jean-Francois Tanguay, Mikhail Ruda, P Gabriel Steg, Pierre Theroux, Stephen D Wiviott, Ian Laws, Marc S Sabatine, David A Morrow
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor losmapimod attenuates inflammation and may improve outcomes. OBJECTIVE: To evaluate the efficacy and safety of losmapimod on cardiovascular outcomes in patients hospitalized with an acute myocardial infarction...
April 19, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27036918/2016-acc-aha-guideline-focused%C3%A2-update-on-duration-of-dual%C3%A2-antiplatelet-therapy-in-patients-with-coronary-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association-task%C3%A2-force%C3%A2-on%C3%A2-clinical-practice-guidelines
#19
Glenn N Levine, Eric R Bates, John A Bittl, Ralph G Brindis, Stephan D Fihn, Lee A Fleisher, Christopher B Granger, Richard A Lange, Michael J Mack, Laura Mauri, Roxana Mehran, Debabrata Mukherjee, L Kristin Newby, Patrick T O'Gara, Marc S Sabatine, Peter K Smith, Sidney C Smith
No abstract text is available yet for this article.
September 6, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27026020/2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy-in-patients-with-coronary-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines-an-update-of-the-2011
#20
keyword
keyword
11431
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"